Solid Biosciences (SLDB) announced that SGT-003, the Company’s investigational gene therapy for Duchenne muscular dystrophy, has been granted an Innovation Passport under the new Innovative Licensing and Access Pathway, ILAP. The Innovation Passport is the entry point for the ILAP, which aims to accelerate time to market and facilitate patient access to new medicines in the UK. The Innovation Passport activates the MHRA and the ILAP partner agencies to develop a product-specific roadmap for regulatory and development milestones.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences price target lowered to $11 from $13 at JPMorgan
- Solid Biosciences price target lowered to $14 from $16 at Citi
- Solid Biosciences Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Solid Biosciences’ SGT-003 Therapy Shows Promising Efficacy and Safety, Earning a Buy Rating
- Solid Biosciences price target lowered to $9 from $10 at Barclays